Skip to main content
Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
16.28
-0.76 (-4.46%)
Nov 12, 2026, 4:00 PM EST - Market closed

Aktis Oncology Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
12.396.51.49--
Revenue Growth
122.77%336.92%---
Gross Profit
-55.07-60.95-39.47-25.92-
Operating Income
-103.73-74.68-52.05-34.79-19.76
Net Income
-87.55-63.73-43.98-28.64-17.93
Earnings Per Share
-2.18-78.34-62.46-46.55-34.65
EPS Growth
-----

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
492.93226.79297.1797.86128.6
Total Debt
10.8411.5512.0113.41.78
Net Cash (Debt)
482.09215.24285.1684.46126.82
Net Cash Growth
105.71%-24.52%237.63%-33.40%-
Net Cash Per Share
12.02264.58404.96137.29245.11

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-86.12-64.1314.76-30-18.13
Capital Expenditures
-8.04-9.58-2.86-3.76-2.31
Free Cash Flow
-94.16-73.7111.9-33.77-20.43
Free Cash Flow Growth
-----

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Margin
-837.45%-1149.52%-3500.34%--
Pretax Margin
-706.81%-980.93%-2957.63%--
Profit Margin
-706.81%-980.93%-2957.63%--
FCF Margin
-760.23%-1134.54%800.27%--